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Research for innovative drugs is crucial to contribute to parasitic
infections control and eradication. Inspired by natural antipro-
tozoal triterpenes, a library of 12 hemisynthetic 3-O-arylalkyl
esters was derived from ursolic and oleanolic acids through
one-step synthesis. Compounds were tested on Trypanosoma,
Leishmania and the WI38 cell line alongside with a set of
triterpenic acids. Results showed that the triterpenic C3
esterification keeps the antitrypanosomal activity (IC50�1.6–
5.5 μm) while reducing the cytotoxicity compared to parent
acids. Unsaturation of the ester alkyl chain leads to an activity
loss interestingly kept when a sterically hindered group replaces
the double bond or shields the ester group. An ursane/oleanane
C3 hydroxylation was the only important feature for antileish-
manial activity. Two candidates, dihydrocinnamoyl and 2-
fluorophenylpropionyl ursolic acids, were tested on an acute
mouse model of African trypanosomiasis with significant para-
sitemia reduction at day 5 post-infection for the dihydrocinna-
moyl derivative. Further evaluation on other alkyl/protective
groups should be investigated both in vitro and in vivo.
1. Introduction
Neglected tropical diseases (NTDs) is a collective term qualifying
a group of communicable diseases that prevail in tropical and
subtropical conditions in 149 countries and affect more than
one billion people.[1] They include Human African Trypanoso-
miasis (or African Sleeping Sickness, HAT) and Leishmaniasis
caused by Trypanosoma brucei (T. b) and some twenty species
of Leishmania, respectively.[2] Importantly, only 4% of newly
approved drugs between 2000–2011 were dedicated to NTDs.[3]
T. b is present mainly in sub-Saharan Africa and is transmitted
by a bite of an infected tsetse fly to a mammalian host. The
disease progresses in two stages: at first, T. b resides in the
blood and lymphatic system (hemolymphatic stage) before
crossing the blood-brain-barrier and infecting the central
nervous system (meningoencephalitic stage).[4] Currently, HAT
treatments for stage 1 are pentamidine and suramin for T. b
gambiense and rhodesiense, respectively, while at stage 2 of the
disease, melarsoprol is used against T. b rhodesiense and
eflornithine plus nifurtimox (NECT-nufurtimox-eflornithine com-
bination therapy) for T. b gambiense. All these treatment
options present strong limitations in terms of toxicity (e.g.,
suramin or the arsenical compound melarsoprol), difficulties in
the administration (e.g., slow intravenous injection) or resist-
ance issues (e.g., NECT).[5,6] In late 2018, a positive scientific
opinion was given by EMA (European Medicines Agency) to
fexinidazole and more recently (July 2021) by FDA (Federal
Drug Administration)[7] as first all-oral treatment for both stage-
1 and stage-2 of the T. b. gambiense form of sleeping sickness in
patients over six years old weighing more than 20 kg, with non-
neglectable label limitations.[8] Regardless of the successful
efforts of the last decades in controlling HAT, these regions are
still at risk of large-scale epidemic outbreaks. Leishmaniasis is
also a vector-borne disease transmitted by sandflies and
encompasses multiple clinical syndromes, most notably visceral,
cutaneous and mucosal forms. Cutaneous leishmaniasis is
caused by at least ten Leishmania species of the mexicana (L. m)
and braziliensis (L. b) complexes. Parasites inoculation happens
through a sand fly bite followed by a variable incubation period
ranging from one week to many months.[9] It is estimated that
between 600000 to 1 million new cases occur worldwide
annually. Treatment of leishmaniasis caused by L. mexicana
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consists of pentavalent antimonials as pentostam or glucan-
time, directly injected into the ulcer or intramuscularly.[10] In this
context and given the severe therapeutic limitations such as
reduced efficacy due to increased parasite resistance, innovative
drugs with new modes of action are urgently needed for NTDs
control and, possibly, eradication. In this sense, lead repurpos-
ing strategies were demonstrated to be efficient medicinal
chemistry rationale for NTDs hit identification as demonstrated
by the successful case of eflornithine.[11] The interest of
pentacyclic triterpenes (PTs) in parasitology was recently
emphasized in a review reporting some 85 active compounds
on Trypanosoma, Leishmania, Plasmodium and Nematoda.[12] For
instance, tingenin B, a PT quinone methide, has been reported
as the most active PT against T. b. brucei and T. cruzi (IC50<
0.25 μgmL  1) although it was found very cytotoxic.[13] In the
oleanane PTs group, some saponin glycosides named maesaba-
lides (isolated from Maesa balansae) were very active against
Leishmania infantum (IC50=0.007–0.046 μgmL
  1).[14] In this con-
text, very few aromatic ursane and oleanane derivatives were
tested on T. b and L. m species such as L. mexicana mexicana
(L. mm). In more recent research, novel compounds derived
from medicinal plants by in situ hemisynthesis were reported,
highlighting the successful input of medicinal chemistry to
natural lead compounds.[15] Our approach towards the develop-
ment of new antitrypanosomal drugs was based upon the
known antitrypanosomal activity of pentacyclic triterpenic acids
and some of their C3 esters. Recent investigations on tradition-
ally used plants lead to the isolation of antitrypanosomal
triterpenic C3 esters, 3-O-p-E/Z-coumaroyltormentic acids[16]
characterized by a hydroxyl function at the C2 position and a
(E/Z)-3-(4-hydroxyphenyl)acrylate group at C3 with an ursane
skeleton (Supporting Information). This triterpenic mixture has
shown attractive in vitro antitrypanosomal activity (IC50=
0.7 μm) and in vivo parasitemia reduction, yet with some
bioavailability limitations.[16] Considering its promising features
but also the difficulties linked to the plant material availability
or the isolation process, our approach was to pursue a lead
optimization strategy of the natural structure, regularly used in
disease drug discovery. A bioisosteric replacement of the
hydroxylic function with fluorine in the aromatic ring inspired
the generation of some fluorine derivatives.[16] Those derivatives
were tested alongside the non-halogenated ones to assess
whether the functional groups or their position would be
important for the antiparasitic activity. To possibly increase the
stability of the triterpenic esters, sterically hindered esters were
designed to disrupt esterase activity and delay esterase
hydrolysis.[17] Therefore, a concise library of 3-O-ursane and
oleanane derivatives were hemisynthesized. The purpose of this
paper is to report on the synthesis, antiparasitic activity and
make an assessment to structure-activity relationships (SAR) of
a series of C3 esters with triterpenic scaffolds.
2. Results and Discussion
A first screening was done, initially, for a set of triterpenic acids
(Figure 1) indicating ursolic acid 1a as the most active acid,
followed by oleanolic acid 2a. Some other PT free acids (1b,
2b) were indeed endowed with interesting antiparasitic
profiles, but suffered from significant cytotoxicity (Table 1). A
Figure 1. Pentacyclic triterpenic acids tested in vitro with ursane (1a–d, 3) and oleanane (2a–c, 4, 5) skeletons. 1a: ursolic acid; 1b: corosolic acid; 1b’: (3β)-
3,27-dihydroxyolean-12-en-28-oic acid; 1c: asiatic acid; 1c’: tormentic acid; 1d: madecassic acid; 2a: oleanolic acid; 2b: maslinic acid; 2c: arjunolic acid; 2b’:
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specifically designed library was then generated (Scheme 1)
with ursane (6a–d) and oleanane (7a–a’’’) skeletons, maintain-
ing the phenylpropyl ester chain (as the natural active models)
or adding a halogen to the phenyl group. Antiparasitic activity
investigations and structural effects on the biological activity
were analyzed to explore a potential activity/selectivity im-
provement alongside a chemical and more effective drug
production.
2.1. Oleanane and Ursane C3 Hemisynthetic Triperpenic
Esters
The 12 triterpenic esters library was readily synthesized in one
step syntheses with, generally, a low yield (not over 52% in the
best cases). The different in vitro biological activities and their
selectivity indexes are tabulated in Table 1. As a general rule,
most synthesized compounds offered low activity scores
against L. mm. However, several compounds gave high activity
against T. bb along with very attractive selectivity indices (SI) for
compounds in the ursane series (6a-a’’’), giving compounds
fulfilling the criteria for hit selection.[18] The oleanane series of 3-
O-esters (7a–a’’’), while performing adequately in terms of
pharmacological scores, led to discouraging results for the
selectivity index. It was decided, therefore, to halt any further
investigations of these oleanane analogues. On the contrary,
the ursane series (6a--d) showed interesting activity and low
cytotoxicity in most of the cases. On the aromatic moiety, a
fluoro substituent was implemented in the three positions
available, that is, para (6a’), meta (6a’’) and ortho (6a’’’). The
best profile was achieved with the ortho-substitution (6a’’’). The
dihydrocinnamoyl group (6a) displayed interesting data both in
terms of efficacy and selectivity and was chosen as one of the
lead compounds for further structural improvements to possibly
increase the metabolic stability (ester linkage) introducing
elements of steric crowding to the two central methylene
moieties.
This led to an α-methyl derivative (6a’’’’) at the cost of
introducing an additional carbon, and a trans-cyclopropane
derivative (6d) which can be considered as a bioisoster of the
cinnamoyl ester side chain. The synthetic ursonic acid (3)
showed a significant activity decrease compared to the parent
acid (1a) and the 3-phenylproprionate derivative (6a) (Support-
ing Information). This supports the hypothesis of a hydroxylic
Table 1. IC50 (μm)�SD on parasites and cells with relative selectivity indices (SI) of triterpenic acids and synthetic esters of at least 2 repetitions of 3
independent replicates.
Biological activities expressed in IC50 (μM, Mean�SD)
ID Antileishmanial[a] Antitrypanosomal[b] Cytotoxicity[c] SI[d]
Acids
1a 7.03�0.46 2.33�0.22 10.08�1.02 4.3
1b 14.23�6.87 5.28�1.25 18.34�6.22 3.5
1b’ nd 44.37�9.75 >105.77 >2.4
1c 55.23�9.93 13.93�3.79 75.66�10.29 5.4
1c’ 55.42�3.14 22.72�1.56 85.70�2.13 3.8
1d >99.07 49.65�2.81 >190.00 >3.8
2a 19.74�2.03 5.83�0.70 63.26�0.74 10.9
2b 18.41�0.51 6.73�1.00 47.51�8.86 7.1
2b’ nd 47.14�16.31 >105.77 >2.2
2b’’ 23.71�1.58 22.28�3.18 94.49�4.68 4.2
2b’’’ 62.63�1.28 20.59�1.60 55.43�6.40 2.7
2c nd 28.28�5.48 >60.00 >2.1
3 83.28�1.55 9.63�0.67 >109.48 >11.4
4 >106.20 71.75�3.27 164.18�10.32 2.3
5 68.42�4.32 47.79�18.43 29.09�2.37 0.6
Esters
6a >84.97 3.50�1.13 142.01�3.45 40.7
6a’ >82.39 2.45�0.30 >164.90 >67.3
6a’’ >82.39 2.67�0.83 >164.90 >61.5
6a’’’ >82.39 1.66�0.38 >131.92 >79.5
6a’’’’ >82.92 2.17�0.32 >82.99 >38.2
6b >85.20 66.19�0.38 nd
6c >100.25 5.02�2.15 114.89�4.74 22.9
6d >83.21 5.41�0.14 >83.28 >15.4
7a >84.91 2.59�0.87 23.54�6.56 9.1
7a’ >82.39 2.88�1.11 16.33�3.26 5.7
7a’’ >82.39 1.72�0.07 20.74�2.25 12.1





[a] Leishmania mexicana mexicana (promastigotes); [b] Trypanosoma brucei brucei (bloodstream form); [c] human-diploid fibroblast cells (WI38); [d]
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group or an ester function at C3 to be important for the
trypanocide activity. Further efforts are needed to expand the
3-O-derivatives library and improve the synthetic yields.
2.2. In Vitro Antiprotozoal Evaluation and Structural Effects
on the Biological Activity of Triterpenic Acids and
3-O-Triterpenic Esters
As shown in Table 1, 1a and 2a remained the most active
triterpenic acids against T. bb in their series, while activities in
the same range were also observed for the α-2-hydroxylated
derivatives, corosolic (1b) and maslinic acids (2b). Concerning
other 3-OH pentacyclic acids, the C-α-16/21/23/27 hydroxyla-
tion showed deleterious effects on antitrypanosomal activities,
with a significant decrease for one additional hydroxyl group at
C27 (1b’, 2b’), two at C2/21 (1c’) and C2/23 (2c), or three at
C2/6/23 (1d). Previous literature data reported the carboxylic
group at C17 to be important for the (1a) antitrypanosomal
activity, underlying a replacement with an aldehyde group
(uvaol) would lead to an activity reduction more evident when
the carboxylic group is replaced by a methyl one (α-amyrin).
Hoet et al. reported an activity loss on T. bb when (2a)
carboxylic group at C17 is replaced with a CH3 group. The
presence of a ketone or the double bond shift also induced a
significant activity decrease, as observed for ursonic (3), 18β-
glycyrrhetinic (4) and morolic (5) acids.[19] Similarly, 1a with a
keto function at C3, was reported to lose the antitrypanosomal
activity for T. cruzi parasites.[20] For oleanane derivatives, the
activity decrease was also associated with a reduction in
selectivity. The importance of the hydroxylic group at C3 has
been reported for the antitrypanosomal action for both 1a and
2a and the ursane- and oleanane-type pentacyclic
triterpenes.[21] A clear counteracting of anti-T. bb activity loss
Scheme 1. Synthesis of ursane and oleanane esters tested in vitro (3, 6a–d, 6–7a–a’’’ and 6a’’’’). Conditions: i) PCC, (CH3)2CO, DCM; ii) DMAP, DCC, R3OH, Tol,
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happens when the adjacent carbon, C4, is substituted with a
polar group.[20] This indicates that the substituent’s nature and
orientation effect on the activity might depend on parasite
strain as demonstrated for a tri-esterified oleanane derivative,
3β-acetoxy-27-trans-caffeoyloxyolean-12-en-28-oic acid methyl
ester. The latter displayed high selective antitrypanosomal
activity on T. bb but was inactive on T. b. rhodesiense
subspecies.[22] The activity of all tested 3-O-ursane esters, except
the cinnamic one (6b), was similar to 1a with enhanced
selectivity for aromatic esters (6a–a’’’’). For 3-O-oleanane
derivatives, activity remained similar as for 2a except for
hydrocinnamic (7a) and para/meta-fluorophenylpropionic de-
rivatives (7a’–a’’) showing a significantly increased activity but
also higher cytotoxicity, leading to similar selectivity. C3
acetylation (6c) was shown to induce a decrease in activity
smaller than described in the literature. Cunha et al. reported a
loss in activity against T. cruzi of both 1a and 2a after
acetylation.[20] As for the sleeping sickness parasite, single C3
acetylation decreased the activity on T. cruzi trypomastigotes
compared to unesterified acids, with 1a also being the most
active derivative. The number and position of polar groups
affect antitrypanosomal activities, potentially due to steric
hindrance and modified conformation. In this paper, we
showed that the C3 aromatic esterification mainly modified the
cytotoxicity of ursane and oleanane derivatives, giving more
selective or active compounds, respectively. Concerning the
antileishmanial activity of the free acids tested, the most active
compound was 1a (IC50=7.03�0.46 μm), significantly more
active than 2a (IC50=19.74�2.03 μm) (p<0.01). Unlike anti-
trypanosomal activity, all tested esters were inactive (IC50>
50 μm). According to the literature, a C3 acetylation or C3 fatty
acid chain (11C) esterification did not affect the activity,
whereas a slight decrease in IC50 was observed with 17C chain
esterification on L. amazonensis promastigotes.[23] Some tested
unesterified acids were already evaluated on other Leishmania
species responsible for visceral (L. donovani, L. infantum) or
cutaneous (L. amazonensis, L tropica, L. braziliensis) leishmania-
sis. Activities were highly species-dependent, but 1a remained
the most active among the tested compounds. Noteworthy,
esterification may keep the activity and decrease the cytotox-
icity, but it also influences the solubility and lipophilicity,
depending on the nature of the aryl/alkyl group, as well as
introducing a hydrolysable function. These problems should be
addressed with appropriate formulations for further in vivo
investigation.
2.3. In Vivo Antitrypanosomal Evaluation of Promising C3
Triterpenic Esters
The range of active compounds was assessed according to their
in vitro antitrypanosomal profile, leading to the selection of two
hits for the in vivo test: the hydrocinnamic (6a) and the ortho-
fluorophenylpropionic (6a’’’) esters of 1a. Ursolic acid 1a was
also tested as comparative corresponding 3-OH triterpenic acid.
All compounds were evaluated for their absence of toxicity in
an acute mice model. No compound induced any acute
symptoms at the highest tested cumulative dose of 100 mgkg  1
by the IP injection route. In the antitrypanosomal assay realized
with a single dose of compounds, no parasitemia difference
between each treated group was observed at the end of the
experiment (Figure 2), neither any survival impact, except for
positive controls. On day 4, no important parasitemia reduction
was seen, whereas at day 5, we observed a significant (p�0.05)
reduction compared to vehicle-treated mice with an estimated
mean inhibition percentage of 61.2�27.8% for treatment with
6a (Figure 3). These SEM values emphasized the high para-
sitemia variability even with a very aggressive strain, very likely
to be linked to the adaptive immune response. 1a and 2a,
indeed, already showed immunomodulatory effects with pro- or
anti-inflammatory activities associated with dose and
environment.[24] This work also showed that the tested com-
pounds were not effective enough to control or delay parasite
growth. However, an earlier and/or longer treatment with a
more appropriate dose should be tested for the hydrocinnamic
Figure 2. Trypanosoma brucei brucei growth expression heat map, showing
the parasitemia (log(T. bb)/mL) between day 3–14 post-infection after
administration of 1a (50 mgkg  1), 6a (50 mgkg  1), 6a‘‘‘ (40 mgkg  1) in
comparation with T-(vehicle) and C+ (suramin) (0.5 mgkg  1). For this experi-
ment, 7 mice were used as negative control (T-); 4 mice as positive control
(C+); 5 mice for 1a, 5 mice for 6a, 6 mice for 6’’’. The chromatic scale
represents equivalent log number of organisms per milliliter of blood.
Figure 3. Estimated parasitaemia (%) day 4 and 5 post-infection (Mean� -
SEM) normalised with T-. For this experiment, 7 mice were used as negative
control (T-); 4 mice as positive control (C+); 5 mice for 1a, 5 mice for 6a, 6
mice for 6’’’. Non-parametric Mann–Whitney in one tailed (in comparison to
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derivative 6a to further investigate the observed parasitemia
decrease. Triterpenic esters 6a, 6a’’’ and 1a were tested here in
an acute African trypanosomiasis in vivo model for the first
time. The used 427 strain is known to induce acute disease with
rapid exponential parasite growth, only controlled by highly
potent drugs, as observed with suramin given at a 100-fold
lower dose. Further investigation of 1a and derivatives on other
less aggressive models to assess compounds potential are
needed, for example on the GVR35 strain.
3. Conclusion
Among the tested PT acids, none was more active against the
evaluated parasites than ursolic acid 1a, with the highest
activity against Trypanosoma brucei brucei. Esterification with a
lipophilic aromatic chain on C3 did not appear to improve
antileishmanial activities for which the presence of a C3
hydroxyl group appeared to be important. Concerning the
antitrypanosomal activity, C3 triterpenic esterification has a
positive impact on the cytotoxicity of triterpenes while keeping
the activity in close range of the parent acids. Different
improvements were observed on ursane and oleanane skel-
etons: 3-O-aromatic ursane derivatives showed an increased
selectivity, whereas some oleanane derivatives showed in-
creased activity. According to hydroxyl and ester positions,
some intramolecular hydrogen bonds can occur, affecting
biological activities, as well as a steric hindrance and preferred
conformation modifying target interaction. Adding a steric
shield in the proximity of the ester function or a bioisoster
replacement of the double bond in the alkyl chain showed a
positive effect on the antitrypanosomal activity and cytotoxicity
which can potentially increase the ester stability, too. Other
esterified derivatives with increased hydroxylation numbers on
the aromatic ring should be tested to assess the antiparasitic
potential of both combined features. In this work, new
antiparasitic scaffolds and activities were reported for known
acids/esters as well as for newly hemisynthesized esters. Some
displayed interesting in vitro antitrypanosomal activity and the
in vivo potential has to be further investigated. The influence of
different alkyl/protective groups should be evaluated to con-
tinue structure-activity relationships studies.
Experimental Section
Reagents and HPLC-MS conditions
Commercial reagents and solvents were obtained from AvaChem
Scientific, VWR Chemicals, Extrasynthese, Phytolab, Sigma-Aldrich
and Acros Organics in the grades puriss, p.a or purum and were
used without further purification. The identification of hemisynthe-
sized compounds was realized on a Bruker Avance spectrometer for
1H NMR and 13C NMR recorded in MeOD or CDCl3. The processing
and evaluation of the spectra were performed using the program
MestReNova 6.0. The resonance multiplicity is indicated as s
(singlet), d (doublet), t (triplet) and m (multiplet) or a combination
of them, and the coupling constants (J) are given in Hz. The mass
spectra were obtained with an LC–HRMS/MS system consisting of a
Thermo Accela pump, autosampler, photodiode array detector and
Thermo Scientific LTQ Orbitrap XL mass spectrometer. High-
resolution MS and MS2 of the major peaks were analysed with an
APCI or ESI source in the negative or positive modes. The following
inlet conditions were applied: capillary temperature 250 °C, APCI
vaporizer temperature 400 °C, sheath gas flow 25.00 u.a., auxiliary
gas flow 25.00 u.a., sweep gas flow 5.00 u.a and discharge current
5 μA; with capillary voltage and tube lens of   10 V and   125 V or
9 V and 70 V in negative and positive mode, respectively. Data
acquisition and processing were performed with Xcalibur software
2.2.
General Chemistry
Syntheses of 6a–b, 6d and 7a–a’’’. Hemi-synthesis was adapted
from Lee et al.[25] and summarized in Scheme 1. A flame-dried
50 mL round-bottomed flask, equipped with stirring bar, reflux
condenser with a septum cap, argon inlet (through septum cap)
and syringe inlet (through another septum cap), was charged with
25 mL of dry toluene, 1.3 equiv. of DCC, 0.04 equiv. of 4-(dimeth-
ylamino) pyridine, and 2.2 equiv. of cinnamic or hydrocinnamic
acids (6a, 6b, 7a) or ortho/meta/para fluorophenylpropionate acid
isomers (6a’–6a’’’ and 7a’–7a’’’) or trans-2-phenyl-1-cyclopropane-
carbonyl chloride (6d). Then, 1 equiv. of purchased triterpenic acid
was added. The resulting solution was brought to 80 °C and stirred
for 24 h. After the reaction was completed, the syringe apparatus
was removed and the reaction mixture was cooled to room
temperature. Stirring was continued for 30 min, at which time no
DCC was detected by TLC analysis (10% EtOAc-Toluene). Further
TLC analysis in two solvent systems revealed the formation of the
desired ester (0.55<Rf<0.7 in 15% EtOAc-Toluene). The mixture
was washed 3 times with AcOEt/water and the organic phase was
dried over MgSO4 and evaporated. The residue was taken up in a
minimal amount of toluene and purified through a silica gel column
(Merck, silica gel 60, 0.065–2 mm) slurry-packed in toluene. Elution
was performed with a gradient of toluene-ethyl acetate. Recrystal-
lization from methanol afforded the pure desired compounds.
When necessary, an additional purification step by semi-preparative
HPLC was performed with a Phenomenex Luna C18 column (250×
10 mm2 with 5 μm as particle size) on a Shimadzu Prominence
system (LC20-AP pumps and SPD-20AV UV/VIS detector) with 100%
methanol at 3 mlmin  1. The purity of each compound is available
in the Supporting Information and was assessed at 210 nm with the
analytical column (250×4 mm2), a flow rate of 1 mlmin  1 and a
binary solvent system composed with acetonitrile and Milli-Q water
as followed: 50% acetonitrile 0–2 min, 100% acetonitrile 27–
42 min, 50% acetonitrile 43–50 min.
Syntheses of 3 and 6c. The hemi-synthesis of 3-oxo-urs-12-en-28-
oic acid (3) and 3-acetyl ursolic acid (6c) was adapted from
Daneshtalab et al.[26] and Gnoatto et al.,[27] respectively (Scheme 1)
and results compared to literature data. 3-Oxo-urs-12-en-28-oic acid
(3): to a cold solution of 4.1 mmol ursolic acid (1a) in 5 ml acetone-
DCM was added 12.5 mmol of pyridinium chlorochromate (PCC) in
a cold solution of acetone-DCM. The reaction mixture was stirred
overnight on an ice-water bath, concentrated and washed 3 times
with water and DCM. 3-Acetyl ursolic acid (6c): 1 equiv. of ursolic
acid (1a) was dissolved in dry toluene with 8 equiv. of pyridine, and
6 equiv. of acetyl chloride were added step-wise. The reaction
mixture was stirred in an oil bath at 60 °C for about 1 h under a
nitrogen atmosphere, neutralized with 1 m HCl and washed 3 times
with water-DCM. The organic phases of 3 and 6c were dried over
MgSO4, filtered and evaporated. Synthesized esters were purified
on a silica gel flash column (0.063–0.2 mm) with n-hexane-acetone
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In Vitro Studies
Trypanosoma brucei brucei (strain 427) bloodstream forms were
cultivated in vitro in HMI-9 medium (Gibco) containing 10% heat-
inactivated fetal bovine serum, 150 mm l-cysteine and 20 mm β-
mercaptoethanol (Sigma-Aldrich) 507 with 5% CO2 at 37 °C.
Leishmania mexicana mexicana (MHOM/BZ/84/BEL46) promasti-
gotes were cultivated in SDM-79 medium (Gibco) supplemented
with 15% heat-inactivated fetal bovine serum and 5 mgL  1 hemin
(Sigma-Aldrich) with 5% CO2 at 28 °C. The human normal fibroblast
cell line, WI38 (ATCC Number CCL-75), was cultivated in vitro in
DMEM medium containing 4 mm l-glutamine, 1 mm sodium
pyruvate supplemented with 10% fetal bovine serum and
penicillin-streptomycin (100 UIml  1 to 100 μgmg  1) (Sigma-Aldrich)
with 5% CO2 at 37 °C. In vitro tests were performed through the
AlamarBlue assay.[28] The cytotoxicity test was based on the
mitochondrial activity assessment with the MTT tetrazolium salt
dye.[29] All pure compounds were solubilized in DMSO at a
10 mgml  1 stock solution and tested in 96-well microtiter plates in
eight serial three-fold dilutions (concentration range: 50–
0.02 μgml  1 on parasites and 100–0.05 μgml  1 on cells). Pentam-
idine isethionate salt (antileishmanial drug, Sigma-Aldrich, 98%
purity), suramin sodium salt (antitrypanosomal commercial drug,
Sigma-Aldrich >99% purity), and camptothecin (cytotoxic commer-
cial drug, Sigma-Aldrich, 95% purity) were used as positive controls
at an initial concentration of 10, 1, 0.1 or 25 μgml  1, respectively.
Tests were performed at least three times in duplicate or two times
in triplicate for antiparasitic and cells assays respectively. The
activities are defined with the IC50 values calculated on the
inhibition sigmoidal curves and selectivity indices (SI) were
obtained as followed:
SI ¼ðIC50 on mammalian cellsÞ=ðIC50 on protozoanÞ
In Vivo Acute Toxicity and Antitrypanosomal Assay
In vivo acute toxicity and antitrypanosomal tests were performed
according to DNDi guidelines on female NMRI mice (6 weeks,
25.9�3.5 g or 7–8 weeks, 28.2�3.6 g respectively, Envigo).[18]
Evaluated pure compounds 1a, 6a and 6a’’’ and positive controls
were solubilized in 10% Tween80/EtOH (7 :3) in sterile water and
given intraperitoneally (IP). For acute toxicity evaluation, the
highest tolerated dose was assessed on two mice groups receiving
four increasing doses every two hours (10, 15, 25 and 50 mgkg  1)
or four times 20 mgkg  1 doses for the ortho-fluorophenylpropio-
nate ursolic acid (6a’’’). Mice were carefully observed after each
injection and each day until autopsy after 48 h. The body weight
and haematocrit were monitored and main organs (heart, liver,
lungs, kidneys and spleen) weights were compared to vehicle
control mice ones. For antitrypanosomal activity evaluation, groups
of at least 5 infected mice (with 104 T. bb on day 0) were treated
with 50 mgkg  1 ursolic acid (1a), 50 mgkg  1 ursolic acid phenyl-
propionate (6a) or 40 mgkg  1 ortho-fluorophenylpropionic ursolic
acid (6a’’’) IP during 5 consecutive days (day 3 to 7 post-infection).
The negative control (7 mice) received the vehicle and positive
controls were given suramin (4 mice) at 0.5 mgkg  1day  1. Para-
sitaemia was estimated with the Herbert and Lumsden matching
method almost every day and compared to negative control mice
as survival evolution.[30] All animal studies were designed according
to the internationally recognized guidelines and approved by the
Ethical Committee for the animals used at the Health Sciences
Sector of the Catholic University of Louvain (2017/UCL/MD/017).
Statistical Analysis
In vitro data were analysed by Graphpad Prism statistical software
and presented as the mean� standard deviation. Differences
between two independent experiments were analysed by the non-
parametric Mann-Whitney test or the Wilcoxon signed-rank test for
comparison to a highest tested concentration and between several
comparing groups by the non-parametric ANOVA (Kruskal-Wallis
and Dunn’s post-test) in two-tailed. In vivo results were presented
as mean� standard error of the mean and analysed by Mann-
Whitney test in one-tailed. Statistical significance for all statistical
tests was set at p�0.05.
Supporting Information
Molecular characterization and spectral information of all synthetic
molecules are reported. Synthetic scope and limitation are
described. All the statistical IC50 and SI analyses obtained in this
work are also available.
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